Relapsed Hodgkin Lymphoma in Older Patients: A Comprehensive Analysis From the German Hodgkin Study Group
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Relapsed Hodgkin Lymphoma in Older Patients: A Comprehensive Analysis From the German Hodgkin Study Group
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 31, Issue 35, Pages 4431-4437
Publisher
American Society of Clinical Oncology (ASCO)
Online
2013-11-05
DOI
10.1200/jco.2013.49.8246
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
- (2012) R. Chen et al. BLOOD
- Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study
- (2012) S. J. Proctor et al. BLOOD
- Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation
- (2012) A. K. Gopal et al. BLOOD
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- State of the art in the treatment of Hodgkin lymphoma
- (2012) Peter Borchmann et al. Nature Reviews Clinical Oncology
- Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009
- (2011) J. Sjoberg et al. BLOOD
- Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma
- (2011) B. Boll et al. BLOOD
- A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era
- (2011) A. M. Evens et al. BLOOD
- How I treat relapsed and refractory Hodgkin lymphoma
- (2011) J. Kuruvilla et al. BLOOD
- High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma
- (2011) N Puig et al. BONE MARROW TRANSPLANTATION
- How we treat elderly patients with Hodgkin lymphoma
- (2011) Magnus Björkholm et al. CURRENT OPINION IN ONCOLOGY
- Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group
- (2011) Peter Borchmann et al. JOURNAL OF CLINICAL ONCOLOGY
- The Unique Characteristics and Management of Patients Over 60 Years of Age with Classic Hodgkin Lymphoma
- (2011) Teresa V. Halbsguth et al. Current Hematologic Malignancy Reports
- Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)
- (2010) T. V. Halbsguth et al. BLOOD
- Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial
- (2010) Hans Theodor Eich et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma
- (2010) Andreas Josting et al. JOURNAL OF CLINICAL ONCOLOGY
- Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes
- (2010) Utz Krug et al. LANCET
- Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma
- (2010) Andreas Engert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study
- (2009) Andreas Engert et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search